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Abstract
4-Hydroxynonenal (HNE), a lipid peroxidation end product, is
produced abundantly in osteoarthritic (OA) articular tissues, but
its role in bone metabolism is ill-defined. In this study, we tested
the hypothesis that alterations in OA osteoblast metabolism are
attributed, in part, to increased levels of HNE. Our data showed
that HNE/protein adduct levels were higher in OA osteoblasts
compared to normal and when OA osteoblasts were treated
with H2O2. Investigating osteoblast markers, we found that HNE
increased osteocalcin and type I collagen synthesis but inhibited
alkaline phosphatase activity. We next examined the effects of
HNE on the signaling pathways controlling cyclooxygenase-2
(COX-2) and interleukin-6 (IL-6) expression in view of their
putative role in OA pathophysiology. HNE dose-dependently
decreased basal and tumour necrosis factor-α (TNF-α)-induced
IL-6 expression while inducing COX-2 expression and
prostaglandin E2  (PGE2) release. In a similar pattern, HNE
induces changes in osteoblast markers as well as PGE2 and IL-
6 release in normal osteoblasts. Upon examination of signaling
pathways involved in PGE2 and IL-6 production, we found that
HNE-induced PGE2 release was abrogated by SB202190, a
p38 mitogen-activated protein kinase (MAPK) inhibitor.
Overexpression of p38 MAPK enhanced HNE-induced PGE2
release. In this connection, HNE markedly increased the
phosphorylation of p38 MAPK, JNK2, and transcription factors
(CREB-1, ATF-2) with a concomitant increase in the DNA-
binding activity of CRE/ATF. Transfection experiments with a
human COX-2 promoter construct revealed that the CRE
element (-58/-53 bp) was essential for HNE-induced COX-2
promoter activity. However, HNE inhibited the phosphorylation
of IκBα and subsequently the DNA-binding activity of nuclear
factor-κB. Overexpression of IKKα increased TNF-α-induced IL-
6 production. This induction was inhibited when TNF-α was
combined with HNE. These findings suggest that HNE may
exert multiple effects on human OA osteoblasts by selective
activation of signal transduction pathways and alteration of
osteoblastic phenotype expression and pro-inflammatory
mediator production.
Introduction
Lipid peroxidation (LPO) is a process initiated by lipid reaction
with reactive oxygen species (ROS). ROS are generated dur-
ing normal cellular metabolism or under oxidative stress stimuli
(for example, cytokine and UV radiation). Polyunsaturated fatty
acids of cellular membrane lipids are targets of ROS attack
and undergo LPO, leading to the formation of chemically reac-
tive lipid aldehydes capable of diffusing from their site of origin.
Similar to ROS, aldehydes can cause severe damage to
nucleic acids and proteins, altering their functions and leading
to the loss of both structural and metabolic function of cells.
Under intense oxidative stress, aldehyde levels increase and
take part in numerous pathological conditions such as cancer,
arthritis, arthrosclerosis, and cardiac diseases[1]. 4-Hydrox-
ynonenal (HNE) is the principal α,  β-unsaturated aldehyde
formed from LPO of both ω-3 and ω-6 polyunsaturated fatty
ALPase = alkaline phosphatase; ATF-2 = activating transcription factor-2; Col I = type I collagen; COX-2 = cyclooxygenase-2; CREB-1 = CRE-bind-
ing factor-1; CT = threshold cycle; DN = dominant negative; ECM = extracellular matrix; ELISA = enzyme-linked immunosorbent assay; ERK = extra-
cellular signal-regulated kinase; FBS = foetal bovine serum; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; HNE = hydroxynonenal; IKKα 
= IkappaB kinase alpha; IL-6 = interleukin-6; JNK = c-Jun NH2-terminal kinase; MAPK = mitogen-activated protein kinase; MDA = malondialdehyde; 
NF-κB = nuclear factor-κB; OA = osteoarthritic; OC = osteocalcin; LPO = lipid peroxidation; PCR = polymerase chain reaction; PGE2 = prostaglan-
din E2; ROS = reactive oxygen species; TNF-α = tumour necrosis factor-α; TTBS = 20 mM Tris, pH7.4, 150 mM NaCl, 0.1% Tween 20; UNG = 
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acids[2]. The accumulation of HNE exhibits a wide range of
biological activities, including stimulation of neutrophil migra-
tion, mitochondrial enzyme inhibition, and activation of stress-
signaling pathways via transcription factors and protein kinase
pathways, as well as inhibition of the nuclear factor-κB (NF-
κB) signaling pathway [3-6].
Osteoarthritis (OA) is a degenerative disease characterised by
a progressive degradation of articular cartilage accompanied
with secondary inflammation of synovial membranes. Although
major progress has been made in the last few years, the aeti-
ology, pathogenesis, and progression of this disease are not
fully understood. Recent clinical and research findings sug-
gest that oxidative stress-induced LPO products can play an
important role in the pathogenesis of OA. Grigolo and col-
leagues [7] were the first to demonstrate that the formation of
HNE and malondialdehyde (MDA) is enhanced in synoviocytes
from patientswith OA. In a recent study, we have shown that
HNE level is higher in synovial fluids of patients with OA com-
pared with normal subjects and in human articular OA
chondrocytes exposed to ROS donors. In addition, we have
reported novel mechanisms linking HNE to OA cartilage deg-
radation. These mechanisms emphasise the implication of
HNE in transcriptional and post-translational modifications of
type II collagen and matrix metalloproteinase-13 in human OA
chondrocytes, and result in cartilage extracellular matrix (ECM)
degradation[8]. However, little is known about the role of HNE
in bone.
Abnormal subchondral trabecular bone remodelling is present
in patients with OA. The increased stiffness of OA bone with
subchondral bone plate sclerosis results in increased trabec-
ular thickening and decreased trabecular space volume/bone
mineralisation with the bone cell defects[9]. Type 1 collagen
(Col I) and other specific osteoblast phenotypic markers, such
as osteocalcin (OC) and alkaline phosphatase (ALPase), are
released from osteoblasts during bone formation[10]. It is
believed that alterations in osteoblast metabolism play an
important role in this disease by producing excess bone-
resorbing cytokines and prostaglandins[11]. Among the pro-
inflammatory mediators, interleukin-6 (IL-6) is a multifunctional
cytokine involved in osteoclast recruitment and differentiation
into mature osteoclast. Prostaglandin E2 (PGE2), produced
primarily by cyclooxygenase-2 (COX-2) [12], plays an impor-
tant role in the local regulation of bone formation and bone
resorption[13]. These biologically active mediators are also
considered to be biochemical markers of bone metabolism
and are regulated in bone by pro-inflammatory cytokines.
The objective of this study was to investigate the role of HNE
in OA osteoblast metabolism by determining its effect on the
production of biological markers and pro-inflammatory media-
tors. Furthermore, we explored the signaling pathways
involved in HNE-regulated IL-6 and PGE2 production.
Materials and methods
Osteoblast culture
Normal human osteoblasts were purchased from PromoCell
GmbH (Heidelberg, Germany) and were cultured according to
the manufacturer's specifications. OA osteoblasts were iso-
lated from trabecular bone specimens from patients suffering
from advanced OA and undergoing primary total knee replace-
ment. The experimental protocol was approved by the
Research Ethics Board at Sacre-Cæur Hospital of Montreal.
The osteoblast cell cultures were prepared as already
described[11]. Briefly, trabecular bone samples were cut into
small pieces of 2 mm2 prior to their sequential digestion in the
presence of 1 mg/ml collagenase type I (Sigma-Aldrich Can-
ada Ltd., Oakville, ON, Canada) in BGJb media (Invitrogen
Canada Inc., Burlington, ON, Canada) without serum at 37°C
for 30, 30, and 240 minutes. After being washed with the
same media, the digested bone pieces were cultured in 25
cm2 plastic cell culture flasks (Corning Incorporated, Corning,
NY, USA) with BGJb media containing 20% foetal bovine
serum (FBS) (Invitrogen Life Technologies). This medium was
replaced every 2 days until cell outgrowths appeared around
the explants. At confluence, cells were split once and plated at
50,000 cells per cm2 in culture plates (Falcon, Lincoln Park,
NJ, USA) with Ham's F-12/Dulbecco's modified Eagle's
medium (HAMF-12/DMEM) (Sigma-Aldrich Canada Ltd.) con-
taining 10% FBS and 50 mg/ml ascorbic acid and grown to
confluence again. Only first-passage cells were used in our
experiments.
HNE assay
Normal and OA osteoblasts were incubated for 24 hours with
or without increasing concentrations of H2O2 (1 to 100 μM).
Total cellular levels of HNE/protein adducts were assessed in
cellular extracts of osteoblasts using an in-house enzyme-
linked immunosorbent assay (ELISA) as previously described
[5].
Determination of OC level and ALPase activity
Osteoblasts were incubated for 24 hours in HAMF-12/DMEM
containing 2% charcoal-stripped FBS, which yields maximal
stimulation of ALPase activity and OC secretion. Cells were
then incubated for 48 hours in the same medium in the pres-
ence of increasing concentrations of HNE (0 to 20 μM). The
medium was collected at the end of the incubation and frozen
at -80°C prior to assay. Cells were washed twice with phos-
phate-buffered saline, pH 7.4, and solubilised in ALPase buffer
(100 mM glycine, 1 mM MgCl2, 1 mM ZnCl2, 1% Triton X-100;
pH 10.5) for 60 minutes with agitation at 4°C. Cellular ALPase
activity was determined as the release of p-nitrophenol hydro-
lysed from p-nitrophenyl phosphate (12.5 mM final concentra-
tion) at 37°C for 30 minutes after cell solubilisation in ALPase
buffer as described above. Protein determination was per-
formed by the bicinchoninic acid method[14]. Nascent OC
was determined by a specific enzyme immunoassay (Biomed-
ical Technologies, Inc., Stoughton, MA, USA). The detectionAvailable online http://arthritis-research.com/content/8/6/R159
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limit of this assay is 0.5 ng/ml, and 2% charcoal-treated FBS
contains less than 0.1 ng/ml of OC.
IL-6 and PGE2 assays
For the HNE dose-response curves, osteoblasts were incu-
bated in 0.5% FBS/HAMF-12/DMEM for 48 hours with
increasing concentrations of HNE (0 to 20 μM). After incuba-
tion, the culture medium was collected and the IL-6 and PGE2
levels were determined using specific commercial kits from
R&D Systems, Inc. (Minneapolis, MN, USA) and Cayman
Chemical Company (Ann Arbor, MI, USA), respectively,
according to the manufacturers' specifications. The sensitivi-
ties of the assays were 3 and 9 pg/ml, respectively.
Protein detection by Western blotting
Osteoblasts were incubated in fresh medium containing 0.5%
FBS/HAMF12/DMEM in the presence of increasing concen-
trations of HNE (0 to 20 μM) for 24 hours or in the presence
of 20 μM of HNE for increasing periods of incubation. Twenty
to 50 μg of cellular protein extract was subjected to discontin-
uous 4% to 12% SDS-PAGE under reducing conditions and
transferred onto nitrocellulose membrane (Bio-Rad Laborato-
ries, Inc., Hercules, CA, USA). The membranes were
immersed overnight at 4°C in a blocking solution consisting of
TTBS (20 mM Tris, pH7.4, 150 mM NaCl, 0.1% Tween 20)
and 5% skim milk and incubated again overnight in blocking
buffer containing the polyclonal rabbit anti-COX-2 or anti-Col
I (1:1,000 dilution; Oncogene Research Products, San Diego,
CA, USA). The membranes were then washed three times with
TTBS and incubated for 1 hour at 22°C with the second anti-
body (anti-rabbit immunoglobulin G-horse radish peroxidase;
New England Biolabs Ltd., Mississauga, ON, Canada) and
washed again. Detection was carried out using Supersignal
west dura extended duration substrate (Pierce Biotechnology,
Inc., Rockford, IL, USA). Membranes were prepared for auto-
radiography and exposed to clear-blue x-ray film (Pierce) and
then subjected to a digital imaging system (Bio-Rad Laborato-
ries, Inc.). For the total and phosphorylated level of mitogen-
activated protein kinases (MAPKs) (p38, c-Jun NH2-terminal
kinase [JNK] 1/2, and extracellular signal-regulated kinase
[ERK] 1/2) as well as transcription factors (activating tran-
scription factor-2 [ATF-2], CRE-binding factor-1 [CREB-1],
and IκBα), we used specific PhosphoPlus kits (New England
Biolabs Ltd.).
Real-time quantitative reverse transcriptase-polymerase 
chain reaction
Total RNA was extracted from OA osteoblasts using TRIzol®
reagent (Invitrogen Life Technologies) according to the manu-
facturer's recommendations. The RNA was quantitated using
the RiboGreen RNA quantitation kit (Molecular Probes, now
part of Invitrogen, Carlsbad, CA, USA), dissolved in RNase-
free H2O, and stored at -80°C until use. One microgram of
total RNA was reverse-transcribed using Moloney murine leu-
kaemia virus reverse transcriptase (Fermentas Canada Inc.,
Burlington, ON, Canada) as detailed in the manufacturer's
guidelines. One fiftieth of the reverse transcriptase reaction
was analysed by real-time quantitative polymerase chain reac-
tion (PCR). The nucleotide sequence of primers are shown
below:
ALPase [15]: 5'-CCCAAAGGCTTCTTCTTG-3' (sense)
5'-CTGGTAGTTGTTGTGAGCAT-3' (anti-sense),
OC [15]: 5'-ATGAGAGCCCTCACACTCCTC-3' (sense)
5'-GCCGTAGAAGCGCCGATAGGC-3' (anti-sense),









glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [19]:
5'-CAG AAC ATC ATC CCT GCC TCT-3' (sense)
5'-GCT TGA CAAAGT GGT CGT TGA G-3' (anti-sense).
Quantitative PCR analysis was performed in a total volume of
50 μl containing template DNA, 200 nM of sense and anti-
sense primers, 25 μl of SYBR® Green master mix (Qiagen Inc.,
Mississauga, ON, Canada), and uracil-N-glycosylase (UNG)
(0.5 Units; Epicentre Biotechnologies, Madison, WI, USA).
After incubation at 50°C for 2 minutes (UNG reaction) and at
95°C for 10 minutes (UNG inactivation and activation of the
AmpliTaq Gold enzyme), the mixtures were subjected to 40
amplification cycles (15 seconds at 95°C for denaturation and
1 minute for annealing and extension at 60°C). Incorporation
of SYBR® Green dye into PCR products was monitored in real
time using a GeneAmp 5700 Sequence detection system
(Applied Biosystems, Foster City, CA, USA) allowing determi-
nation of the threshold cycle (CT) at which exponential amplifi-
cation of PCR products begins. After PCR, dissociation
curves were generated with one peak, indicating the specifi-
city of the amplification. The CT value was obtained from each
amplification curve using the software provided by the manu-
facturer (Applied Biosystems). Preliminary experimentsArthritis Research & Therapy    Vol 8 No 6    Shi et al.
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showed that the amplification efficiency of COX-2, ALPase,
OC, Col α1, IL-6, and GAPDH was similar.
Relative amounts of mRNA in normal and OA cartilage were
determined using the standard curve method. Serial dilutions
of internal standards (plasmids containing cDNA of target
genes) were included in each PCR run, and standard curves
for the target gene and for GAPDH were generated by linear
regression using log (CT) versus log (cDNA relative dilution).
The CT values were then converted to number of molecules.
Relative mRNA expression in cultured chondrocytes was
determined using the ΔΔCT method, as detailed in the manu-
facturer's guidelines (Applied Biosystems). A ΔCT value was
first calculated by subtracting the CT value for the housekeep-
ing gene GAPDH from the CT value for each sample. A ΔΔCT
value was then calculated by subtracting the ΔCT value of the
control (unstimulated cells) from the ΔCT value of each treat-
ment. Fold changes compared with the control were then
determined by raising 2 to the ΔΔCT power. Each PCR reac-
tion generated only the expected specific amplicon as shown
by the melting-temperature profiles of the final product and by
gel electrophoresis of test PCR reactions. Each PCR was per-
formed in triplicate on two separate occasions for each inde-
pendent experiment.
Nuclear extract preparation and electrophoretic mobility 
shift assay
OA osteoblasts were incubated with HNE alone or in combi-
nation with 1 ng/ml tumour necrosis factor-α (TNF-α) for 1
hour. Nuclear extracts were prepared and electrophoretic
mobility shift assay (EMSA) was performed as previously
described[20]. Double-stranded oligonucleotide probes for
CRE (5'-AGAGATTGCCTGACGTCAGAGAGCTAG-3') and
NF-κB (5'-AGTTGAGGGGACTT TCCCAGGC-3') were end-
labeled with [γ-32P]-ATP using a kit (Promega Corporation,
Madison, WI, USA). The binding reactions were conducted
with 5 μg of nuclear extract and of 2 × 105 cpm of [γ-32P]-
labeled oligonucleotide probe at 22°C for 20 minutes in a final
volume of 10 μl, and complexes were resolved on non-dena-
turing 6% polyacrylamide gels. Then, gels were fixed, dried,
and exposed to clear-blue x-ray film (Pierce).
Supershift assays were performed as described above with
nuclear extracts from cells treated with HNE (20 μM) or TNF-
α (1 ng/ml) for 1 hour. Two micrograms of the antibodies were
added to the shift reaction mixture 20 minutes after the incu-
bation period, followed by another incubation at 4°C overnight.
The antibodies were specific for the transcription factors ATF-
2, p65, and p50 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA).
Plasmids and transient transfections
The human COX-2 promoter constructs used included a wild-
type (WT) (-415)-Luciferase (Luc) COX-2 promoter plasmid,
mutated ATF/CRE (-58/-53) (-415)-Luc COX-2 promoter
plasmid, and mutated NF-κB (-223/-214) (-415)-Luc COX-2
promoter plasmid, as previously described [21]. Expression
vectors for WT (pCMV-Flag-p38) and dominant negative (DN)
(pCMV-Flag-p38) p38 MAPK were a kind gift from Dr. R.J.
Davies (University of Massachusetts). Expression vector for
IKKα was generously given by Dr. M. Karin (University of Cali-
fornia). A pCMV-β-galactosidase (pCMV-β-gal) reporter vec-
tor was purchased from Promega Corporation.
Human MG-63 osteoblast-like line cells (American Type Cul-
ture Collection, Manassas, VA, USA) (approximately 50% con-
fluence) were transiently transfected in 12-well cluster plates
using lipofectamine 2000™ reagent methods (Invitrogen Life
Technologies) according to the manufacturer's protocol.
Briefly, transfections were conducted for 6 hours with DNA
lipofectamine complexes containing 10 μl of lipofectamine
reagent, 2 μg DNA plasmid, and 0.5 μg of pCMV-β-gal (as a
control of transfection efficiency). After washing, medium was
replaced by a fresh medium containing 1% FBS and experi-
ments were performed in this medium supplemented with the
factors under study. For promoter study, Luciferase activity
was determined in cellular extracts by a kit (Luciferase Assay
System; Promega Corporation) using a microplate luminome-
ter (Applied Biosystems) and normalised to β-gal level, which
was quantified by a specific ELISA (Roche Diagnostics Can-
ada, Laval, QC, Canada). To study the effect of p38 MAPK
and IKKα overexpression on PGE2 and IL-6 production, cells
were transfected with the appropriated WT p38 MAPK, DN
p38 MAPK, or IKKα expression vector as described above and
then culture medium was collected for PGE2 and IL-6 assay as
described above.
Statistical analysis
The data are expressed as the mean ± standard error of the
mean. Statistical significance was assessed by unpaired Stu-
dent t test, and P < 0.05 was considered significant.
Results
HNE production in OA osteoblasts
To provide evidence that HNE production was increased dur-
ing OA development, the level of this aldehyde was deter-
mined in cellular extract of normal and OA osteoblasts. As
shown in Figure 1a, HNE/protein adduct levels were 1.4-fold
higher in OA cells compared with the normal (p ≤ 0.05). To
confirm that OA osteoblasts are able to produce HNE under
oxidative stress, cells were incubated for 24 hours with
increasing concentrations of H2O2 and levels of HNE/protein
adducts were quantified in cellular extracts. The data showed
that H2O2 at different concentrations induces the formation of
HNE/proteins adducts in OA osteoblasts in a dose-dependent
manner (Figure 1b).Available online http://arthritis-research.com/content/8/6/R159
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Changes in differentiation markers (ALPase and OC) and 
Col I
Because ALPase, OC, and Col I are the principal biomarkers
of osteoblasts and considered to be good indicators for bone
formation and metabolic activity, we tested the ability of HNE
to alter their expression and, in turn, the phenotype of the oste-
oblasts. Figure 2 depicts the variation in osteoblast production
of ALPase (Figure 2a,b), OC (Figure2c,d), and Col I (Figure
2e,f) after HNE incubation. Compared with control, HNE dose-
dependently inhibited significantly osteoblast ALPase activity
by 19.6%, 25.4%, and 32.1% (p < 0.01) in the presence of 5,
10, and 20 μM of HNE, respectively (Figure 2a). However,
ALPase mRNA expression was significantly inhibited only at
20 μM HNE (20%; p < 0.05) (Figure 2b).
In contrast to the inhibition of ALPase, OC protein level was
increased significantly in the presence of HNE (15%, 25%,
and 20% at 5, 10, and 20 μM, respectively; p < 0.05) (Figure
2c). OC mRNA levels were also increased at different concen-
trations of HNE, with a maximum stimulation of 155% at 5 μM
HNE (p < 0.01) (Figure 2d).
Finally, we explored the effect of HNE on Col I, which consti-
tutes 90% of the total organic ECM in mature bone. Our data
showed that HNE increased Col I protein expression by fac-
tors of 2.4, 2.1, 4.6, and 8.4 at concentrations of 1, 5, 10, and
20 μM, respectively (Figure 2e), although this inductive effect
of HNE was not manifested at the mRNA level (Figure 2f).
HNE inhibits IL-6 expression
To determine whether HNE is a modulator of IL-6 production,
osteoblasts were incubated with 0 to 20 μM of HNE for 48 or
4 hours for IL-6 protein and mRNA determination, respectively.
As shown in Figure 3, there was a significant dose-dependent
inhibition of IL-6 protein release (Figure 3a) and mRNA expres-
sion (Figure 3b) after incubation of osteoblasts with increasing
concentrations of HNE. To test the combined effect of HNE
with TNF-α, osteoblasts were preincubated with HNE (20 μM)
for 30 minutes and then stimulated with TNF-α (1 ng/ml).
Compared with untreated cells, TNF-α significantly induced
IL-6 release by 549% (Figure 3c). This induction was com-
pletely inhibited in the presence of 20 μM HNE (47% of
untreated cells). At mRNA level, HNE also showed a signifi-
cant (approximately 70%) decrease of TNF-α-induced IL-6
mRNA expression (Figure 3d).
HNE induces PGE2 release and COX-2 expression
To better characterise the properties of HNE cell signaling in
OA osteoblasts, we evaluated COX-2 gene expression and
PGE2 production in response to HNE stimulation. Compared
with untreated cells, PGE2 level was increased significantly by
209%, 240%, 551%, and 2,434% at concentrations of 1, 5,
10, and 20 μM HNE, respectively (Figure 4a). The increase of
PGE2 production related directly to an increase in COX-2 pro-
tein and mRNA OA osteoblasts. The protein and mRNA levels
were increased in a dose-dependent manner by incubation of
cells with HNE (0 to 20 μM), with a maximal stimulation at 20
μM HNE (8.5- and 4.6-fold, respectively) (Figure 4b,c).
To delineate the signaling pathways involved in HNE-induced
COX-2 expression in pilot experiments, we used cell-permea-
ble chemical inhibitor of p38 MAPK, SB202190. This inhibitor
had no effect on the basal PGE2 release (data not shown). As
shown in Figure 4d, HNE significantly induced PGE2 release
by 340% in comparison with untreated cells. However, the
p38 MAPK inhibitor significantly reduced HNE-stimulated
Figure 1
Determination of HNE/protein adduct concentrations in normal (N) and  osteoarthritic (OA) osteoblast Determination of HNE/protein adduct concentrations in normal (N) and 
osteoarthritic (OA) osteoblast. HNE/protein adduct levels were meas-
ured by enzyme-linked immunosorbent assay in cellular extracts from 
untreated (a) or treated (b) osteoblasts with increasing concentrations 
of H2O2 for 24 hours at the indicated concentrations. HNE/protein 
adduct levels were expressed in picograms of HNE/protein adducts 
per milligrams of total proteins. Data are mean ± standard error of the 
mean (n = 3). Statistics: Student unpaired t test; *p < 0.05, **P < 0.01, 
***P < 0.001. HNE, 4-hydroxynonenal.Arthritis Research & Therapy    Vol 8 No 6    Shi et al.
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PGE2 production. Identical results were obtained with COX-2
protein level (data not shown).
HNE modulates ALPase, OC, IL-6, and PGE2 in normal 
osteoblasts
Next, we examined whether HNE can also modulate the activ-
ity of ALPase as well as the production of OC, PGE2, and IL-
6 in normal osteoblasts. In a similar pattern, our data showed
that HNE at 20 μM inhibits ALPase activity (Figure 5a) and IL-
6 production (Figure 5c) but, in contrast, induced OC (Figure
5b) and PGE2 (Figure 5d) release.
HNE activates p38 MAPK and JNK1/2, but not ERK1/2
To gain insight into the signaling pathway activated by HNE in
human OA osteoblasts, we first examined the HNE-induced
phosphorylation patterns of MAPKs over increasing periods of
time. Our data indicated that HNE stimulated p38 MAPK
phosphorylation within 5 minutes and remained in a phospho-
rylated state for 120 minutes (Figure 6a). JNK2 (p46) was
phosphorylated in a time-dependent manner, reaching a maxi-
mum between 5 and 30 minutes and returning to the basal
level at 60 minutes. HNE had no effect on the ERK1/2 phos-
phorylation levels. No change in the total protein level of
MAPKs was noted (data not shown).
HNE induced ATF-2/CREB activation but inhibited NF-κB
Next, we investigated the effect of HNE on p38 MAPK down-
stream transcription factors CREB-1 and ATF-2. Our data
showed that exposure of 20 μM HNE resulted in an early phos-
phorylation of ATF-2 and CREB-1 after 5 minutes of incuba-
Figure 2
Effect of HNE on osteoblast markers ALPase, OC, and Col I Effect of HNE on osteoblast markers ALPase, OC, and Col I. Human osteoarthritic osteoblasts were incubated with increasing concentrations of 
HNE for 48 hours and then ALPase activity (a) and Col I protein level (e) were determined in cellular extract as described in Materials and methods. 
The OC release (c) was determined in culture medium by enzyme-linked immunosorbent assay. For mRNA level, cells were incubated for 4 hours in 
the absence or presence of indicated concentrations of HNE, total RNA was isolated and reverse-transcribed into cDNA, and ALPase (b), OC (d), 
and Col I (f) were quantified using real-time polymerase chain reaction. All experiments were performed in triplicate, and negative controls without 
template RNA were included in each experiment as indicated in Materials and methods. mRNA levels were normalised to those of GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase) mRNA. Data are means ± standard error of the mean of n = 3 and expressed as a percentage of untreated 
cells. Statistics: Student unpaired t test; *p < 0.05, **p < 0.01. ALPase, alkaline phosphatase; Col I, type I collagen; HNE, 4-hydroxynonenal; OC, 
osteocalcin.Available online http://arthritis-research.com/content/8/6/R159
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tion (Figure 6a). We also examined the effect of HNE on the
total NF-κB/p65 and phosphorylated IκBα. Our data showed
that HNE had no significant effect on the basal level of the
phosphorylated IκBα and cytosolic and nuclear NF-κB/p65 in
osteoblasts (data not shown). However, combined with TNF-
α, HNE inhibited strongly NF-κB/p65 protein translocation in
the nucleus in a dose-dependent manner (Figure 6b).
HNE increased DNA binding of ATF/CRE, but decreased 
DNA binding of NF-κB
To explore the effect of HNE on DNA-binding activity of ATF/
CRE and NF-κB, OA osteoblasts were incubated for 60 min-
utes with 20 μM HNE or 1 ng/ml TNF-α. The latter was used
as a positive control of NF-κB activation. EMSA data showed
that HNE increased the DNA-binding activity of ATF/CRE to
170% compared with unstimulated cells (Figure 6c). How-
ever, TNF-α (but not HNE) induced the DNA-binding activity of
NF-κB by 160% (Figure 6d). Basal and induced binding was
displaced by adding 50-fold excess cold ATF/CRE and NF-κB
oligonucleotide (competition).
To further identify the ATF/CRE and NF-κB protein complexes
that bind on these motifs, specific anti-ATF-2, anti-p65, and
anti-p55 antibodies were added to the shift reaction mixture.
As illustrated in Figure 6c,d, the ATF-2 was supershifted in
HNE-treated osteoblasts, and the p65 and p50 proteins were
supershifted in TNF-α-treated osteoblasts.
HNE induced COX-2 promoter activity via CRE site
To examine for elements of transcriptional control of the COX-
2 gene stimulated by HNE, we conducted transient transfec-
tion analyses with a WT (-415)-Luc COX-2 promoter con-
struct harbouring enhancer elements [21-23] for critical
transcription factors, including an ATF/CRE site (-58 to -53).
Data showed that HNE (20 μM) as well as TNF-α (1 ng/ml)
upregulated the COX-2 promoter activity by 7.8- and 8.4-fold,
Figure 3
Effect of HNE on IL-6 protein production in osteoblasts Effect of HNE on IL-6 protein production in osteoblasts. Osteoblasts were treated with HNE (0 to 20 μM) for 48 or 4 hours for IL-6 protein (a) (n = 
7) and mRNA (b) (n = 3) determination, respectively. The effect of HNE combined with TNF-α was evaluated by incubating osteoblasts with HNE 
(20 μM) for 30 minutes and subsequently stimulating them with TNF-α (1 ng/ml) for 48 or 4 hours for IL-6 protein (c) (n = 7) and mRNA (d) (n = 3) 
determination, respectively. mRNA levels of each gene were quantified by real-time polymerase chain reaction as described in Materials and meth-
ods and normalised to those of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA. Data are means ± standard error of the mean and 
expressed as a percentage of untreated cells. Statistics: Student unpaired t test; *p < 0.05, **p < 0.01, ***p < 0.001. HNE, 4-hydroxynonenal; IL-6, 
interleukin-6; TNF-α, tumour necrosis factor-α.Arthritis Research & Therapy    Vol 8 No 6    Shi et al.
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respectively, compared with control (Figure 7). The mutation
of the ATF/CRE site decreased the basal COX-2 promoter
activity. In addition, their inducibility by either HNE or TNF-α
was completely abrogated. However, the mutation of proximal
NF-κB site (-223/-214) in the human COX-2 promoter con-
struct was without effect in terms of basal and HNE-stimulated
luciferase activity.
IL-6 and PGE2 modulation by HNE is related to IKKα and 
p38 MAPK signaling pathways, respectively
Finally, for a better understanding of the role of IKKα in NF-κB-
mediated IL-6 production, constitutive activated IKKα was
overexpressed in MG-63 osteoblast-like cells and then cells
were incubated with TNF-α, HNE, or TNF-α combined with
HNE. Our data showed that IKKα overexpression stimulated
IL-6 production in the presence of 1 ng/ml TNF-α, an effect
completely abrogated by HNE (Figure 8a). These results indi-
cated that the inhibition of the IKKα pathway is the major reg-
ulator of the IL-6 response to HNE.
To further confirm that p38 MAPK plays a principal role in
mediating HNE-induced COX-2 in osteoblasts, we trans-
fected expression vectors of WT p38 MAPK and DN p38
MAPK followed by HNE stimulation. Overexpression of WT
p38 plasmid markedly increased PGE2 production, and HNE
treatment further enhanced PGE2 release compared with con-
trol cells (Figure 8b). However, the overexpression of DN p38
MAPK abrogated this effect.
Discussion
This study was aimed at clarifying the regulation of OA oste-
oblast activity by HNE, a very reactive aldehyde produced dur-
ing ROS-induced LPO. One major finding of this study was an
alteration in the production of ALPase, OC, and Col I by oste-
oblasts after HNE exposure. Also, HNE up to 20 μM did not
alter the cell viability but at 50 μM was cytotoxic and signifi-
cantly decreased the cell viability (approximately 40%) com-
pared with untreated cells (data not shown). Based on these
data, all subsequent experiments were conducted using HNE
up to 20 μM. The mechanism of HNE cytotoxicity was demon-
strated in various cell types and tissues and is believed to be
related to the chemical modification of cellular proteins by
HNE. Among a number of proteins modified by HNE, citric
acid cycle enzymes and cytochrome C oxidase were detected
as the major targets of HNE in cells[5,24,25]. On the other
hand, exposure of cells to HNE resulted in rapid reduction of
cellular glutathione levels, suggesting that HNE influences pri-
marily the redox status of the cells[26].
Firstly, we demonstrated that HNE (at ≤10  μM) reduced
ALPase activity without changing its expression. These data
suggest the existence of a post-translational mechanism that
decreases ALPase activity, possibly through HNE binding.
This is based on previous reports showing that H2O2 and glu-
cose mediate post-translational modification of this enzyme
Figure 4
Effect of HNE on PGE2 release and COX-2 expression Effect of HNE on PGE2 release and COX-2 expression.(a) Osteoblasts 
were treated with HNE (0 to 20 μM) for 48 hours, and PGE2 release 
was evaluated in culture medium by PGE2 enzyme immunoassay kit. (b, 
c) Osteoblasts were treated with HNE (0 to 20 μM) for 48 or 4 hours 
for protein and mRNA determination, respectively. COX-2 protein 
expression (b) and mRNA expression (c) were evaluated by Western 
blot and real-time reverse transcriptase-polymerase chain reaction, 
respectively. Quantifications of COX-2 protein and mRNA levels were 
normalised, respectively, to those of β-actin protein and GAPDH (glyc-
eraldehyde-3-phosphate dehydrogenase) mRNA. (d) Cells were prein-
cubated in the absence or presence of p38 MAPK inhibitor SB202190 
(10 μM) for 30 minutes, followed by incubation by HNE (20 μM) for 48 
hours. PGE2 secretion was evaluated as described above. Data are 
means ± standard error of the mean of n = 3 and expressed as a per-
centage of untreated cells. Statistics: Student unpaired t test; *p < 
0.05, ***p < 0.001. COX-2, cyclooxygenase-2; HNE, 4-hydroxynone-
nal; MAPK, mitogen-activated protein kinase; PGE2, prostaglandin E2.Available online http://arthritis-research.com/content/8/6/R159
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and, in turn, enzyme inactivation[27,28]. Because bone
ALPase is a transmembrane protein, and the membrane is a
source of HNE production by LPO process, we suggest that
ALPase would be more susceptible to attack by this aldehyde.
With the ultimate goal of determining whether ALPase was a
target for HNE, we have incubated bovine recombinant
ALPase with increasing concentrations of HNE. Our prelimi-
nary data showed that this aldehyde inhibits enzyme activity in
a dose-dependent manner (study in progress). Given that
ALPase is one of the markers of osteoblast phenotypic differ-
entiation and plays an important role in bone formation, the
observed decrease in its activity in response to HNE exposure
supports the hypothesis that this molecule prevents osteob-
last differentiation/mineralisation. Our data are in agreement
with those of Parhami and colleagues [29] and Mody and col-
leagues [30], showing that lipid oxidation products inhibit
osteoblastic differentiation of marrow stromal cells as demon-
strated by inhibition of ALPase activity. ALPase participates in
the differentiation of osteoblasts and provides phosphate for
hydroxyapatite mineral formation. Its inhibition by HNE could
therefore lead to impaired bone mineralisation[31].
Secondly, in contrast to ALPase, OC expression at protein
and mRNA levels was significantly increased after treatment
with HNE (1 to 20 μM). OC is synthesised predominately by
osteoblasts and represents the most osteoblast-specific gene.
Glowacki and colleagues [10] supported the hypothesis that
OC may function as a matrix signal in the recruitment and dif-
ferentiation of bone-resorbing cells. Because OC is limited to
the osteoblast, analysis of its expression in vitro provides
important information about terminal osteoblast differentiation
[32]. Increased bone formation is observed in OC knockout
mice[33]. These findings underline the importance of OC in
bone turnover, suggesting that OC retards bone formation/
mineralisation[34]. Therefore, the increased OC levels in
Figure 5
Comparison of the effect of HNE on normal (N) and osteoarthtitic (OA) osteoblast metabolism Comparison of the effect of HNE on normal (N) and osteoarthtitic (OA) osteoblast metabolism. Cells were incubated in the absence or presence of 
20 μM HNE for 48 hours. ALPase activity (a) was determined in cellular extract as described in Materials and methods. OC (b), IL-6 (c), and PGE2 
(d) levels were measured in culture media using specific kits. Data are means ± standard error of the mean of n = 3 and expressed as a percentage 
of untreated cells. Statistics: Student unpaired t test; *p < 0.05, **p < 0.01, ***p < 0.001. ALPase, alkaline phosphatase; HNE, 4-hydroxynonenal; IL-
6, interleukin-6; OC, osteocalcin; PGE2, prostaglandin E2.Arthritis Research & Therapy    Vol 8 No 6    Shi et al.
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HNE-treated osteoblasts indicate that HNE plays an important
role in regulation of osteoblastic bone formation functions.
Thirdly, we demonstrated that HNE induces Col I α1 expres-
sion in human osteoblasts at the protein, but not at the mRNA,
level. This may indicate that HNE upregulates Col I synthesis
at the post-transcriptional step, but we cannot explain this find-
ing at this time. Further investigations will be performed to
explain why HNE does not affect the mRNA level of Col I by
determining RNA-binding proteins. Among them, alphaCP
protein was identified as having a critical role in mRNA stabili-
sation of Col I. The induction of Col I synthesis by HNE in oste-
Figure 6
Effect of HNE on signaling pathways Effect of HNE on signaling pathways. (a, b) Osteoblasts were treated with 20 μM HNE for the indicated times in the presence or absence of 1 ng/
ml TNF-α. Total cell lysates or nuclear extracts (approximately 50 μg) were prepared and subjected to Western analysis with anti-phosphospecific 
antibodies anti-phospho-p38 MAPK, anti-phospho-JNK1/2, anti-phospho-ERK1/2, anti-phospho-ATF-2 and anti-phospho-CREB-1, and anti-NF-κB/
p65. (c, d) Osteoblasts were incubated in absence (control) or presence of 1 ng/ml TNF-α, 20 μM HNE, or 20 μM HNE combined with 1 ng/ml 
TNF-α in serum-free medium for 1 hour. Nuclear extracts were prepared and subjected to electrophoretic mobility shift assay using ATF/CRE (c) and 
NF-κB (d) oligonucleotide probes. Specificity of the binding was assayed by competition (comp) of the oligonucleotide with 50-fold of excess unla-
beled ATF/CRE or NF-κB oligonucleotide or by the adding specific antibodies anti-ATF-2, anti-p50, or anti-p65. Arrows refer to specific DNA–pro-
tein complex. Data are representative of three to five independent expriments. ATF-2, activating transcription factor-2; CREB-1, CRE-binding factor-
1; ERK, extracellular signal-regulated kinase; HNE, 4-hydroxynonenal; JNK, c-Jun NH2-terminal kinase; MAPK, mitogen-activated protein kinase; NF-
κB, nuclear factor-κB; TNF-α, tumour necrosis factor-α.Available online http://arthritis-research.com/content/8/6/R159
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oblasts suggests that this aldehyde contributes to the
elevation of collagen deposition in OA bone and supports
other reports. Parola and colleagues [35] were the first to
demonstrate that HNE upregulates Col I in human hepatic fat-
storing cells. In another study, Garcia-Ruiz and colleagues
[36] demonstrated that MDA upregulates Col I through activa-
tion of Sp1 transcription factor. It has been reported that HNE
acted as a potent pro-fibrogenic stimuli in the expression of
genes involved in ECM deposition in hepatic fat-storing cells
[35]. Nevertheless, our findings that HNE potentially acts as a
pro-fibrogenic stimulus to induce Col I production in osteob-
lasts suggest a possible link between oxidant stress and OA
trabecular subchondral bone fibrosis.
In our study, we considered it essential to address several
potential factors, such as IL-6 and PGE2, that play a critical
role in bone resorption. Our previous study reported that OA
subchondral and trabecular osteoblasts produce more IL-6
and PGE2 levels than normal cells[37]. We demonstrate here
that HNE inhibits basal and TNF-α-induced IL-6 expression at
both protein and mRNA levels in osteoblasts via the NF-κB
signaling pathway. We have detected significant changes in
total IκBα and a slight decrease of phosphorylated IκBα.
Moreover, no translocation of NF-κB/p65 from cytosol to the
nucleus was observed in HNE-treated osteoblasts. This
observation was confirmed by NF-κB-binding activity and
IKKα overexpression. We demonstrated that HNE inhibits
TNF-α-induced NF-κB binding. Interestingly, HNE completely
blocked the IKKα-enhanced TNF-α-induced IL-6 production.
These data are consistent with other studies suggesting that
HNE exerts its inhibitory action at the IKKα level or upstream,
thereby affecting subsequent IκBα phosphorylation/proteoly-
sis[38]. The inhibition of NF-κB system by HNE and preven-
tion of degradation of IκBα are associated with certain
alterations of expression of the NF-κB target gene product,
such as inducible nitric oxide synthase [39] and IL-6[40]. As
indicated, the regulation of IL-6 expression is governed pre-
dominantly by the ubiquitously expressed transcription factor
NF-κB, which is required for the inducible expression of genes
associated with inflammatory responses[41]. The report of
Dendorfer and colleagues [42] indicated that mutations in the
NF-κB site of IL-6 promoter completely abolished lipopolysac-
charide-induced promoter activity in murine monocyte-macro-
phage cell line PU5-1.8. Altogether, our findings combined
with the existing literature indicate that HNE inhibits IL-6
expression at the transcriptional level via NF-κB signaling
pathways.
COX-2 and PGE2 levels were markedly increased in osteob-
lasts treated with HNE. We demonstrated that the p38 MAPK
pathway played a key role in the mechanism of HNE-induced
PGE2 expression. We observed that HNE stimuli elicited a
rapid and significant phosphorylation of p38 MAPK in osteob-
lasts. Next, we tested the effect of a p38 MAPK-specific inhib-
itor, SB202190, on PGE2 release. Our data showed that
SB202190 blocked completely the HNE-induced PGE2 pro-
duction. Furthermore, the overexpression of WT p38 MAPK
enhanced PGE2 expression, and conversely DN p38 MAPK
decreased HNE-induced PGE2  levels. Kumagai and col-
leagues[43] have proposed for the first time the implication of
p38 MAPK in HNE-induced COX-2 in epithelial cells. The
authors have demonstrated that HNE enhances COX-2
expression by the stabilisation of COX-2 mRNA via the p38
MAPK pathway. In COX-2 promoter, numerous cis-elements
are identified to exert transcriptional control of COX-2[22,44].
Among these elements, ATF/CRE was shown to act as the
Figure 7
Functional analysis of COX-2 promoter in MG-63 osteoblast-like line cells Functional analysis of COX-2 promoter in MG-63 osteoblast-like line cells. The -415 constructs of the COX-2 promoter fused to a Luciferase (Luc) 
reporter gene, its mutated ATF/CRE derivative (muATF/CRE), and mutated NF-κB derivative (muNF-κB) are shown in schematic representation. The 
constructs were co-transfected in MG-63 osteoblast-like line cells with pCMV-β-galactosidase (pCMV-β-gal). Six hours after transfection, fresh 
0.5% foetal bovine serum/Dulbecco's modified Eagle's medium was added in the absence or presence of 20 μM HNE, 1 ng/ml TNF-α, and 20 μM 
HNE + 1 ng/ml TNF-α for another 24 hours. The β-gal and Luc levels were then measured in cellular extracts using specific commercial kits, and 
data were normalised for Luc and β-gal activities. Values are mean ± standard error of the mean of three experiments. Statistics: p values determined 
by Student unpaired t test: ***p < 0.001. P values are versus autologous untreated cells (control). COX-2, cyclooxygenase-2; HNE, 4-hydroxynone-
nal; NF-κB, nuclear factor-κB; TNF-α, tumour necrosis factor-α.Arthritis Research & Therapy    Vol 8 No 6    Shi et al.
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most critical of these regulatory elements for COX-2 transcrip-
tion[21]. Mutation in the ATF/CRE sequence attenuates HNE-
stimulated COX-2 promoter activity. Mutating the more proxi-
mal NF-κB in the human COX-2 promoter construct was with-
out effect in the basal and HNE-stimulated luciferase activity,
suggesting that the NF-κB site in the promoter region of COX-
2 gene is not involved in the HNE-induced COX-2 expression.
In many cell types, the ATF/CRE site is activated by homodim-
ers and heterodimers of c-Jun, c-Fos, and ATF/CRE family
members subsequent to serum, 12-O-tetradecanoylphorbol-
13-acetate, or growth factor stimulation. HNE was shown to
induce ATF-2 and CREB-1 phosphorylation and DNA-binding
activity of the ATF/CRE site. Under different cytokines and
growth factors, NF-κB and ERK1/2 are known regulators of
COX-2 expression[45,46]. However, neither IκBα degrada-
tion nor translocalisation of NF-κB from cytoplasm to the
nucleus was observed by western blotting analysis and ERK1/
2 kinase was not phosphorylated by HNE treatment. This
observation indicates that NF-κB and ERK1/2 are not involved
in the HNE-induced COX-2 expression.
Conclusion
In this study, we identified for the first time a novel mechanism
linking oxidative stress to nuclear signaling in OA osteoblasts
through the action of HNE, an LPO end product. Our data sug-
gest that HNE may contribute in OA development via its ability
to alter cellular phenotype and metabolic activity of osteob-
lasts. In the light of the previous data on increased HNE levels
in OA articular tissues, particular interest should be addressed
to the pathophysiological role of this aldehyde in OA.
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